Amryt Pharmaceuticals lifted by sales and acquisition

1 mins. to read
Amryt Pharmaceuticals lifted by sales and acquisition
Master Investor Magazine

Master Investor Magazine 56Never miss an issue of Master Investor Magazine – sign-up now for free!

Read the latest Master Investor Magazine

AIM-listed rare and orphan disease specialist Amryt Pharmaceuticals (LON:AMYT) has seen its share price rise by 2.42% to 122.90p (as of 12:00 GMT) after it reported revenue growth of 19.7% for the nine months to 30th September. The company completed the purchase of Aegerion Pharmaceuticals in late September and now has two commercial stage assets that it is working to commercialise in multiple markets.

CEO Dr. Joe Wiley commented: “The first nine months of 2019 have been momentous and transformational for Amryt. Through the acquisition of Aegerion, we have evolved from a company with a single asset on the market in EMEA to become a global biopharmaceutical company with two orphan disease products and a commercial infrastructure across North America, EMEA and LATAM.

“For the nine-month period to 30 September 2019, pro-forma revenues of the combined company have grown by 19.7% compared with the same period in 2018. Myalept has continued to grow in the US where the product is approved for Generalized Lipodystrophy, and we are now in the active launch-phase of Myalepta in EMEA, where this product is approved for both Generalized and Partial Lipodystrophy. It has been pleasing to see Lojuxta continue to deliver revenue growth and we are now implementing in the US a similar strategy to that used to significantly grow Lojuxta in Europe.

“Looking to our pipeline, our late stage development asset, AP101, for the treatment of wound-related complications in EB, continues to enrol patients in the Phase 3 study following the encouraging outcome of interim safety and efficacy analyses conducted by the Independent Data Monitoring Committee. The study is on track to be fully enrolled in the coming months.

“Amryt is now very well positioned to execute on our strategy of becoming a global leader in the rare and orphan disease space and most importantly, delivering therapies to patients with unmet needs“.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *